ArticleJournal of natural medicines2026
Three new phenolic glycosides from root bark of Periploca sepium and their hypoglycemic activity.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Three new phenolic glycosides (1-3) and four known compounds were isolated from the ethanol extract of the root bark of Periploca sepium. Their chemical structures were elucidated based on comprehensive spectroscopic analyses, including high-resolution electrospray ionization mass spectrometry (HR-ESI-MS), 1D and 2D nuclear magnetic resonance (NMR) spectra. The sugar moieties were determined via acid hydrolysis followed by comparison with standard sugars. The hypoglycemic activity was evaluated by α-glucosidase and α-amylase inhibition assays. All four phenolic glycosides exhibited inhibitory activity against α-glucosidase and α-amylase with IC₅₀ values below 100 µM. Among them, compound 1 exhibited the strongest α-glucosidase inhibitory activity with an IC₅₀ value of 17.25 ± 1.39 µM, which was significantly better than that of the positive control acarbose (IC₅₀ = 111.2 ± 0.35 µM). Meanwhile, compound 2 showed the most potent α-amylase inhibitory activity with an IC₅₀ value of 30.99 ± 0.92 µM, also superior to acarbose (IC₅₀ = 149.63 ± 0.64 µM). Molecular docking results indicated that compounds 1-4 had strong binding affinity with α-glucosidase and α-amylase (ΔG < -6 kcal/mol), which further demonstrated that the four phenolic glycosides from P. sepium exerted their inhibitory effects on the two key enzymes through stable molecular binding interactions. These results suggested that the phenolic glycosides from P. sepium could be served as potential lead compounds for the development of anti-diabetic agents.
Indexed as
Identifiers
42814340What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.